{"release":"wpf-claim-checks","version":"1.5.0","checkedOn":"2026-11-16","verificationLabel":"AI-assisted source verification","humanReview":"none recorded","claim":{"id":"weight-loss-results-comparable","claimWording":"Tirzepatide caused more weight loss than semaglutide, because its trial showed a bigger percentage.","wordingKind":"representative","quoted":null,"title":"When weight-loss results can be compared","peptides":["tirzepatide","semaglutide","retatrutide"],"aliases":["Mounjaro","Zepbound","Wegovy","Ozempic"],"topics":["interpretation","effectiveness"],"verdict":"overstated","plainAnswer":"Percentages can be compared directly only when both drugs were randomized in the same trial, and WPF found that for one trial in this set (SURMOUNT-5). Two separate placebo-controlled trials differ in people, length and design, so subtracting them proves nothing.","scope":{"population":"Adults with obesity in the five results of Flagship Weight Management 1.3.0","design":"One head-to-head randomized trial, three separate placebo-controlled trials and one observational cohort","boundary":"Weight change as reported. Not safety, cost, tolerability or any individual's expected result."},"strongest":[{"label":"SURMOUNT-5, result surmount-5-weight-72w (Flagship Weight Management 1.3.0)","url":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=surmount-5-weight-72w","kind":"WPF record","population":"751 adults with obesity, without type 2 diabetes","design":"Phase 3b, open-label, randomized head-to-head, 72 weeks","locator":"Point estimates: registry NCT05822830 results, primary outcome measure 1, posts -20.2 (tirzepatide) and -13.7 (semaglutide) as least-squares means, each with a standard error of 0.59, and a between-group least-squares mean difference of -6.5 (95% CI -8.1 to -4.9). The intervals -21.4 to -19.1 (tirzepatide's own mean) and -14.9 to -12.6 (semaglutide's own mean) and P<0.001 are from the NEJM abstract (PMID 40353578), not the registry; each belongs to one arm's mean, not to the difference between arms, and the abstract does not report the between-group difference."},{"label":"STEP 1 and SURMOUNT-1 (separate placebo-controlled trials), results step-1-weight-68w and surmount-1-weight-72w","url":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=step-1-weight-68w","kind":"WPF record","population":"1,961 adults (STEP 1, 68 weeks) and 2,539 adults (SURMOUNT-1, 72 weeks)","design":"Two separate double-blind placebo-controlled trials","locator":"Each compares one drug with placebo; neither contains the other drug, so the two results are an indirect comparison."},{"label":"Observational cohort, result jama-intern-med-2024-realworld","url":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=jama-intern-med-2024-realworld","kind":"WPF record","population":"41,222 US adults; 18,386 after propensity-score matching","design":"Observational cohort, not randomized, on-treatment follow-up to 12 months","locator":"Hazard ratios 1.76, 2.54 and 3.24 for reaching 5%, 10% and 15% weight loss, checked against the open-access full text."}],"uncertain":["SURMOUNT-5 was open-label and its publication abstract does not name the estimand, so the match to the analysis plan was made by method.","Doses, populations and follow-up differ between the placebo-controlled trials, and WPF did not model those differences.","The cohort's differences may reflect factors that were not measured, because people were not randomized."],"wouldChange":["A second randomized head-to-head trial in a different population, which would show whether the SURMOUNT-5 difference holds.","Network meta-analysis methods that adjust for trial differences, if applied and reported transparently."],"gaps":["The four journal papers behind the trial rows returned HTTP 403 to automated requests, so their tables and figures were not located; registry results and analysis plans were read instead (see the Verify panel for each result)."],"searchScope":null,"regulatory":null,"checkedOn":"2026-11-16","links":{"profiles":["/directory/semaglutide","/directory/tirzepatide","/directory/retatrutide"],"films":["/films/metabolic/06-semaglutide"],"flagship":["https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w","https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w","https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w"],"journeys":["/research/journey/semaglutide"],"teaching":["/research/teaching/weight-management-comparison"],"changes":[]},"extends1_0_0":false},"sha256":"79db0f05974da321cc7feab3c31ca679e7fc6684b212d665d220b9028adfd9a9"}